Clinical trial · no report yet · Phase 2
TIDE-A
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
- NCT04698213 ↗
- Unknown
- Consorzio Oncotech
- 15 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 10 | |
| Podcasts | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma (Tide-A Study)
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Renal Carcinoma Metastatic
- Interventions
- Axitinib Oral Tablet; Avelumab
- Arms
- intermittent axitinib plus Avelumab · Experimental
- Enrollment
- 75 (estimated)
- Primary outcomes
- Overall response rate (ORR)
- Sponsor
- Consorzio Oncotech with Clinical Research Technology S.r.l.
- Start
- Oct 7, 2020
- Primary completion
- Sep 2023 (estimated)
- Results posted
- No
- Registry record
- NCT04698213 · updated Jan 6, 2021